Clinica Las Condes S.A.

As of June 30, 2026, Clinica Las Condes S.A. carries a market capitalization of 180.03B, placing it among publicly traded companies globally. Its enterprise value stands at 408.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Clinica Las Condes S.A. has 15.79M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.09, and the price-to-book ratio stands at 0.71.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 408.10B versus a market cap of 180.03B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Clinica Las Condes S.A. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.72, indicating elevated leverage, while an interest coverage ratio of -3.05 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Clinica Las Condes S.A. posted a negative return on equity (ROE) of -19.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.09, reflecting losses generated across the asset base. The company generates approximately 74.13M in revenue per employee across its workforce of 2,505.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 49.45 indicates how many times Clinica Las Condes S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Clinica Las Condes S.A. recorded an income tax benefit of -16.09B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -62.44B and -43.98B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Clinica Las Condes S.A.'s stock has declined approximately 13.16% over the past 52 weeks. The 50-day moving average sits at 13,176.92, while the 200-day moving average is 12,469.55.

Over the twelve months ended June 30, 2026, Clinica Las Condes S.A. generated 185.71B in revenue and converted that into -43.98B in net income, yielding earnings per share of -2,606.66. EBITDA reached -25.51B, while operating income came in at -34.25B.

As of June 30, 2026, Clinica Las Condes S.A. holds 39.26B in cash and equivalents against 269.65B in total debt, resulting in a net debt position of 250.03B. Total book value stands at 255.00B, with working capital of 130.97M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Clinica Las Condes S.A. posted a gross margin of 18.99, reflecting its pricing power and cost economics. The operating margin of -18.44 and net profit margin of -23.68 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -59.02, meaning Clinica Las Condes S.A. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Clinica Las Condes S.A.'s most recent stock split took place on June 17, 2026.

As of June 30, 2026, Clinica Las Condes S.A. has an Altman Z-Score of 0.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.